Harnessing immunoinformatics for developing a multiple-epitope peptide-based vaccination approach against SARS-CoV-2 spike protein

• Published in: Saudi journal of biological sciences Vol. 30; no. 6; p. 103661
• Main Authors: Moustafa, Rehab I., Faraag, Ahmed H.I., El-Shenawy, Reem, Agwa, Mona M., Elsayed, Hassan
• Format: Journal Article
• Language: English
• Published: Saudi Arabia Elsevier B.V 01.06.2023; The Author(s). Published by Elsevier B.V. on behalf of King Saud University
• Subjects: B-epitopes; Immunoinformatics; Original; Peptide vaccine; SARS-CoV-2; T-epitopes; SARS-CoV-2; B-epitopes; T-epitopes; Peptide vaccine; Immunoinformatics
• ISSN: 1319-562X; 2213-7106
• DOI: 10.1016/j.sjbs.2023.103661

COVID-19 has spread to over 200 countries with variable severity and mortality rates. Computational analysis is a valuable tool for developing B-cell and T-cell epitope-based vaccines. In this study, by harnessing immunoinformatics tools, we designed a multiple-epitope vaccine to protect against COVID-19. The candidate epitopes were designed from highly conserved regions of the SARS-CoV-2 spike (S) glycoprotein. The consensus amino acids sequence of ten SARS-CoV-2 variants including Gamma, Beta, Epsilon, Delta, Alpha, Kappa, Iota, Lambda, Mu, and Omicron was involved. Applying the multiple sequence alignment plugin and the antigenic prediction tools of Geneious prime 2021, ten predicted variants were identified and consensus S-protein sequences were used to predict the antigenic part. According to ElliPro analysis of S-protein B-cell prediction, we explored 22 continuous linear epitopes with high scores ranging from 0.879 to 0.522. First, we reported five promising epitopes: BE1 1115-1192, BE2 481-563, BE3 287-313, BE4 62-75, and BE5 112-131 with antigenicity scores of 0.879, 0.86, 0.813, 0.779, and 0.765, respectively, while only nine discontinuous epitopes scored between 0.971 and 0.511. Next, we identified 194 Major Histocompatibility Complex (MHC) ‐ I and 156 MHC ‐ II epitopes with antigenic characteristics. These spike-specific peptide-epitopes with characteristically high immunogenic and antigenic scores have the potential as a SARS-CoV-2 multiple-epitope peptide-based vaccination strategy. Nevertheless, further experimental investigations are needed to test for the vaccine efficacy and efficiency.